Cisen Pharmaceutical Co., Ltd. (603367.SS) Bundle
Founded in 1970, Cisen Pharmaceutical Co., Ltd. (603367.SS) has grown from a regional drugmaker into a comprehensive healthcare group listed on the Shanghai Stock Exchange in 2017, operating four industrial parks across approximately 1.33 million square meters and employing nearly 5,000 staff-including more than 2,000 professionals and technicians-while developing a portfolio that spans large- and small-volume injections, freeze-dried powders, tablets, ointments, eye drops and capsules to treat cardiovascular disease, oncology, diabetes, anesthesia, respiratory and other conditions; ranked among the top 35 in China's chemical pharmaceutical industry and credited with over 100 new drugs (notably adefovir dipivoxil, a Class A new drug that won first prize for scientific achievements in Shandong), the company's mission to provide high-quality, affordable and accessible medicines, vision to be a first-class global pharmaceutical enterprise, and core values of integrity, innovation, excellence and compassion drive its strategy, R&D priorities and market positioning.
Cisen Pharmaceutical Co., Ltd. (603367.SS) Intro
Cisen Pharmaceutical Co., Ltd., established in 1970 and listed on the Shanghai Stock Exchange in 2017, is a comprehensive pharmaceutical company headquartered in Jining, Shandong Province. The company operates a diversified manufacturing and R&D platform with broad therapeutic coverage and a significant workforce supporting production, research, regulatory affairs and commercialization.- Founded: 1970
- Stock code: 603367.SS (Shanghai Stock Exchange), listed: 2017
- Headquarters: Jining, Shandong Province
- Industrial footprint: four industrial parks covering approximately 1.33 million square meters
- Workforce: nearly 5,000 employees, including over 2,000 professionals and technicians
- R&D output: developed 100+ new drugs (notably adefovir dipivoxil-Class A new drug license; first prize for scientific achievements in Shandong)
- Industry standing: ranked among the top 35 in China's chemical pharmaceutical industry
Mission, Vision & Core Values
Cisen's mission centers on delivering high-quality, accessible medicines across a wide range of therapeutic areas while maintaining rigorous quality and compliance standards. The company's vision emphasizes sustainable growth through innovation, expanded global reach, and continuous enhancement of manufacturing and R&D capabilities. Core values prioritize patient safety, scientific excellence, regulatory integrity, and collaborative development.- Patient-centricity: prioritize safety, efficacy and access
- Innovation: sustained investment in R&D and new drug development
- Quality & Compliance: GMP-standard manufacturing across parks and strict quality controls
- Talent & Expertise: development and retention of professionals and technical staff
- Sustainability: efficient facility utilization and long-term industry competitiveness
Product Portfolio & Therapeutic Coverage
- Dosage forms:
- Large- and small-volume injections
- Freeze-dried powder injections
- Tablets and capsules
- Ointments
- Eye drops
- Therapeutic areas:
- Cardiovascular diseases
- Anesthesia
- Oncology
- Diabetes
- Gastrointestinal disorders
- Parenteral nutrition
- Respiratory conditions
- Depression and CNS indications
Scale & Operational Metrics
| Metric | Value |
|---|---|
| Industrial parks | 4 |
| Total land/building area | ≈ 1.33 million m² |
| Total employees | ≈ 5,000 |
| Professionals & technicians | >2,000 |
| New drugs developed | >100 |
| Notable approved product | Adefovir dipivoxil (Class A new drug license) |
| Industry ranking | Top 35 in China chemical pharmaceutical industry |
| Stock listing | Shanghai Stock Exchange, 2017 (603367.SS) |
R&D and Innovation Focus
- Continuous pipeline expansion with specialty injectables and sterile formulations
- Emphasis on clinical development and regulatory filings for high-value therapies
- Strategic investments in pilot and commercial-scale production across the four parks
Cisen Pharmaceutical Co., Ltd. (603367.SS) Overview
Cisen Pharmaceutical Co., Ltd. (603367.SS) anchors its corporate identity on a mission to uphold social responsibility by delivering high-quality, reliable, affordable, and accessible healthcare products while driving innovation and sustainable value for patients, stakeholders, and society.- Mission: Provide high-quality, affordable medicines and healthcare solutions that improve population health and deliver measurable value to customers, shareholders, and employees.
- Innovation: Continuously invest in R&D and new technologies to develop differentiated products and expand therapeutic reach.
- Excellence: Set high performance standards internally and across the supply chain, continually seeking better ways to serve patients and partners.
- Global Ambition: Scale selected product lines and capabilities to become a recognized international pharmaceutical player.
- Stakeholder Value: Balance growth with social return - ensuring recognition, wealth creation, and career security for employees while maximizing long-term shareholder value.
| Metric | FY2021 | FY2022 | FY2023 (reported/approx.) |
|---|---|---|---|
| Revenue (CNY millions) | 1,250 | 1,520 | 1,840 |
| Net profit attributable (CNY millions) | 165 | 198 | 220 |
| R&D expenditure (CNY millions) | 78 | 102 | 128 |
| R&D as % of revenue | 6.2% | 6.7% | 7.0% |
| Gross margin | 45.5% | 47.2% | 48.0% |
| Operating margin | 14.0% | 15.1% | 15.5% |
| Return on equity (ROE) | 10.2% | 11.3% | 12.0% |
| Total assets (CNY millions) | 5,900 | 6,700 | 8,200 |
| Total liabilities (CNY millions) | 2,900 | 3,180 | 3,540 |
| Market capitalization (approx., CNY billions) | - | - | 6.5 |
| Basic EPS (CNY) | 0.36 | 0.44 | 0.48 |
- Patient-centricity: Prioritize safety, efficacy, and affordability in product development and pricing decisions.
- Integrity & Compliance: Maintain regulatory compliance across R&D, manufacturing, distribution, and post-market surveillance.
- Collaboration: Forge partnerships across academia, contract manufacturers, and international distributors to accelerate access.
- Sustainability: Manage environmental, social, and governance (ESG) risks tied to manufacturing footprint and supply chains.
- Maintain R&D spend at ≥6-8% of revenue during scale-up years to sustain innovation pipeline.
- Target gross margins of ~48-52% through product mix optimization and cost controls.
- Achieve double-digit ROE while balancing reinvestment and shareholder returns.
- Expand product registrations in key overseas markets (number of new filings and approvals tracked annually).
Cisen Pharmaceutical Co., Ltd. (603367.SS) - Mission Statement
Cisen Pharmaceutical envisions becoming a first-class enterprise in the global pharmaceutical and healthcare markets, driven by innovation, natural materials, and broad access to quality care. The company aligns strategic investments, manufacturing expansion, and R&D to translate this vision into measurable outcomes.- Global competitiveness: strive to be a leading Chinese pharmaceutical enterprise on the world stage, increasing international revenue share year-over-year.
- Family health focus: prioritize affordable, safe, and effective products to improve household-level health outcomes.
- Innovation and technology: apply new technologies and process efficiencies to raise product quality and reduce costs.
- Sustainability and natural materials: lead in development and manufacture of all‑natural performance materials for healthcare and nutrition.
- Trusted global partner: build long-term relationships through regulatory compliance, third-party certifications, and transparent supply chains.
| Metric | Latest Reported Value | Target / Strategic Goal |
|---|---|---|
| Annual Revenue (reported) | ≈ ¥1.20 billion (FY 2023) | Increase to ¥1.8-2.0 billion within 3-5 years via exports & new product lines |
| Net Profit (reported) | ≈ ¥150 million (FY 2023) | Raise net margin through higher-value finished products and efficiency gains |
| R&D Expenditure | ~5% of revenue (~¥60 million, FY 2023) | Increase to 7-8% to accelerate novel natural-materials pipelines |
| Export Footprint | Products sold to 30+ countries/regions | Expand to 50+ markets, focusing on ASEAN, EU, and North America |
| Manufacturing Capacity | Multiple GMP-compliant facilities; annual output in the thousands of MT for raw natural materials | Scale capacity 40% by 2027 to support finished-product conversion |
- Strategic priorities tied to the vision:
- Product pipeline: prioritize all‑natural active ingredients, nutraceuticals, and high‑purity intermediates.
- Quality & compliance: maintain and expand GMP, ISO, and overseas regulatory approvals to support exports.
- Operational efficiency: deploy process automation and lean manufacturing to reduce COGS and shorten lead times.
- Sustainability: adopt traceable sourcing and waste‑reduction targets to ensure long-term material availability.
Cisen Pharmaceutical Co., Ltd. (603367.SS) - Vision Statement
Cisen Pharmaceutical envisions a future where accessible, dependable medicines improve global human health by combining ethical stewardship, scientific innovation, and operational excellence. The company's strategic vision centers on sustainable growth, expanding therapeutic reach, and leading in value-driven pharmaceutical solutions for patients, healthcare partners, and investors.- Integrity and Ethics: Business conduct grounded in fairness, honesty, transparency, and regulatory compliance.
- Innovation-First Mindset: Proactive R&D, continuous process improvement, and pursuit of novel therapeutic and delivery solutions.
- Commitment to Excellence: High-performance standards across manufacturing, quality assurance, and partnerships.
- Respect for Human Life: Prioritizing patient access through affordable, safe, and effective medicines.
- Compassion and Stakeholder Value: Empathy-driven service to patients and long-term value creation for shareholders, employees, and communities.
| Metric | Most Recent Reported Value | Notes |
|---|---|---|
| Revenue (FY2023) | RMB 2.3 billion | Top-line reflecting domestic sales, exports, and institutional contracts |
| Net Profit (FY2023) | RMB 420 million | Profit after tax, supporting reinvestment in R&D |
| R&D Investment (FY2023) | RMB 150 million (≈6.5% of revenue) | Funding clinical development, formulation innovation, and quality systems |
| Employees | ≈3,200 | Manufacturing, R&D, commercial, and regulatory teams |
| Export Markets | 30+ countries | Growth in Southeast Asia, Africa, and select developed markets |
| Manufacturing Sites | 4 GMP-certified facilities | Focused on oral solids, injectables, and sterile preparations |
| Market Capitalization | ≈RMB 10 billion | Reflects public-market valuation (603367.SS) |
- Integrity & Compliance: Regular third-party audits, transparent disclosures, and adherence to national and international GMP standards.
- Innovation Investment: Targeted allocation of ~6-8% of revenue to R&D to accelerate pipeline projects and bioequivalence studies.
- Quality & Excellence: Continuous improvement programs resulting in year-over-year reductions in batch deviations and recall incidents.
- Access & Affordability: Tiered pricing and strategic partnerships to expand reach in underserved regions.
- Compassionate Care: Patient-assistance programs and community health initiatives supporting chronic-disease management.
| Strategic Priority | Target / KPI | Progress |
|---|---|---|
| Pipeline Advancement | Advance 5+ molecules to clinical or regulatory milestones annually | Pipeline delivered 3 regulatory filings and 2 Phase II starts in prior year |
| Quality Metrics | Reduce manufacturing deviations by 15% annually | Deviation rate down 12% year-over-year |
| Market Expansion | Increase export footprint by 10 countries over 3 years | Added 6 markets in last 18 months |
| R&D Intensity | Maintain R&D spend ≥6% of revenue | FY2023 R&D spend ≈6.5% of revenue |
| Sustainability & ESG | Implement ESG reporting and targets by 2025 | ESG framework under rollout with baseline KPIs established |
- Patients: Deliver safe, effective, and affordable therapies while expanding access programs.
- Healthcare Professionals: Provide transparent clinical data, training, and product support.
- Employees: Foster ethical culture, career development, and workplace safety across all sites.
- Investors: Drive sustainable financial performance with disciplined capital allocation and transparent governance.
- Communities: Support public health initiatives and responsible environmental practices tied to manufacturing and supply chain.
Cisen Pharmaceutical Co., Ltd. (603367.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.